Testosterone Pellets for Hypogonadism

Title: An Open-Label Pilot Study of the Pharmacokinetics and Safety of Testosterone (Testopel) Pellets in Adult Males with Hypogonadism

The purpose of this study is to investigate the blood levels of testosterone and the variability in testosterone concentrations after administration of Testopel. Testopel pellets are testosterone pellets that were approved by the FDA in 1972 for the treatment of hypogonadism.

They are implanted subcutaneously in a simple office procedure. This 18-week study is for men with a documented history of low testosterone for at least 12 months.

PI: Andrew McCullough, MD

For more information: